Paclitaxel - Oasmia Pharmaceutical

Drug Profile

Paclitaxel - Oasmia Pharmaceutical

Alternative Names: Apealea; OAS-PAC-100; Paclical; Paclitaxel micellar - Oasmia Pharmaceuticals; Paclitaxel-XR-17; XR-17-paclitaxel

Latest Information Update: 29 Apr 2016

Price : $50

At a glance

  • Originator Oasmia Pharmaceutical
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Registered Ovarian cancer
  • Phase I Breast cancer

Most Recent Events

  • 27 Apr 2016 Efficacy data from a phase III trial in Ovarian cancer released by Oasmia Pharmaceutical
  • 15 Mar 2016 Biomarkers information updated
  • 08 Feb 2016 Preregistration for Ovarian cancer (Combination therapy) in European Union (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top